Document is current
Any future updates will be listed below
-
Authors
Anabel Sinberger, Liat
Zahavi, Tamar
Sonnenblick, Amir
Salmon‐Divon, Mali
-
Funding
Funding for this research was provided by:
Israel Science Foundation (397/19)
Israel Cancer Association (ICA 20220004)
Ministry of Health, State of Israel (3-18671)
- License Information
-
More Information
Article History
Received: 11 July 2023
Accepted: 21 November 2023
First Online: 27 November 2023
Competing interests
: A.S has received research grants from Novartis and Roche companies, and has an advisory role at Eli Lilly, Pfizer, Novartis, Roche, MSD and AstraZeneca A.S also received travel expenses from Celgene, Medison, Roche and MSD, and was a speaker bureau at Teva, Roche, Pfizer, Novartis and Eli Lilly.
